VIKING GLOBAL INVESTORS LP 13D and 13G filings for Inhibrx Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-06-03 5:56 pm Sale | 2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 0 0.000% | -7,150,826 (Position Closed) | Filing |
| 2024-02-14 10:00 am Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 7,150,826 15.100% | 511,627 (+7.71%) | Filing |
| 2023-02-14 1:18 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 6,639,199 15.200% | 1,333,333 (+25.13%) | Filing |
| 2022-02-14 5:02 pm Unchanged | 2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 5,305,866 14.000% | 0 (Unchanged) | Filing |
| 2021-02-12 7:43 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 5,305,866 14.100% | 180,219 (+3.52%) | Filing |